Presentation is loading. Please wait.

Presentation is loading. Please wait.

Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011 CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, J Kowalska,

Published byMarion Horn Modified over 8 years ago

Similar presentations

Presentation on theme: "Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011 CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, J Kowalska,"— Presentation transcript:

1 Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011 CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, J Kowalska, N Friis-Moeller, AN Phillips, CA Sabin, JD Lundgren for the D:A:D Study Group

2 Background In settings with access to ART, dramatic reductions in AIDS-related mortality have led to increased survival HIV positive individuals may therefore experience a wider range of complications (AIDS vs. non-AIDS) than in previous years It is increasingly important to accurately classify both AIDS-related and non-AIDS related causes of death, and to monitor trends over time

3 Aim To investigate trends over time in the rates of all-cause and cause-specific mortality in the D:A:D Study in 1999- 2011

4 Methods – Study participants Participants included from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) Study: a collaboration of 11 cohorts from Europe, USA and Australia Prospective follow-up for individuals began from 1999 onwards All clinical outcomes, including deaths, are reported in real time, and are centrally validated and categorised From 2004 onwards, deaths were reported using the CoDe form* *see www.cphiv.dk

5 Methods – Participant follow-up Individuals were followed from D:A:D entry to the first of: Death Six months after last clinic visit 1 st February 2011 The primary (underlying) cause of death was considered Causes of death were grouped for analysis: A. AIDS-related B. Cardiovascular disease (CVD) related C.Liver disease related a D.Non-AIDS Malignancies (NADM) related b E.Other/Unknown a Deaths related to chronic viral hepatitis / liver failure not related to viral hepatitis b non-AIDS, non-HCV, non-HBV related malignancies

6 Methods – Statistical analysis Relative rates of the association of calendar time with all cause mortality and with each specific cause of death were calculated Relative rates were then calculated using Poisson regression, adjusting for factors that have potentially changed over time Factors included: Fixed: Age, gender, ethnicity, mode of HIV acquisition Time-updated: HBV status, HCV status, smoking status, diabetes, hypertension, HIV RNA, BMI, CD4 count

7 Baseline characteristics 1 HIV positive individuals (%) Number49734 (100) GenderMale36701 (74) Age (years)Median (IQR)38 (32, 45) Mode of HIV acquisitionIDU7631 (15) Heterosexual16133 (32) Other4069 (8) MSM21901 (44) HCV positive a Yes6449 (13) HBV positive b Yes5425 (11) Smoking statusCurrent17109 (34) Former8521 (17) Never12294 (25) Unknown11810 (24) a HCV antibody positive; b HBsAg positive, HBeAg positive or HBV DNA positive/anti-Hbe positive

8 Baseline characteristics 2 HIV positive individuals (%) Number49734 (100) BMI (kg/m 2 )Median (IQR)23.0 (21.0, 25.3) Hypertension c Yes7861 (16) Diabetes d Yes1260 (3) Total cholesterol (mmol/l)Median (IQR)4.7 (4.0, 5.7) Previous AIDS diagnosisYes10463 (21) CD4 (cells/mm 3 )Median (IQR)400 (242, 590) Exposure to ARTYes30400 (61) Exposure to PIYes20362 (41) Exposure to NNRTIYes14447 (29) c Systolic BP >140 mmHg; Diastolic BP>90 Hg; or receiving anti-hypertensives d Centrally validated endpoint: see www.cphiv.dk

9 Overall death rate 3,802 deaths in 49,734 HIV positive individuals followed for 304,695 person-years Rate: 12.5 per 1,000 person-years 95% CI: 12.1 to 12.9

10 Association between calendar year and mortality: All causes 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year 5 Unadjusted Incidence : 17.4 17.0 15.8 12.0 10.0 8.3 (per 1000 pyrs) 3 2 4 1 0.1 0.5

11 Association between calendar year and mortality: All causes 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted* 5 3 2 4 1 0.1 0.5

12 Causes of death in the D:A:D Study N (%) Total3802 (100) AIDS 1094 (29) Liver-related 499 (13) Chronic viral hepatitis 432 (11) Liver failure 67 (2) CVD-related 421 (11) Myocardial Infarction 218 (6) Stroke 55 (1.4) Other CVD 55 (1.4) Other heart disease 85 (2) Diabetes mellitus complications 8 (0.2) Non-AIDS cancer 535 (14) N (%) Other/ Unknown 1253 (33) Non-AIDS infections 277 (8) COPD 27 (0.7) Pancreatitis 20 (0.5) Renal dysfunction/disease 50 (1.3) Suicide 151 (4) Drug overdose 106 (3) Accident 72 (2) Homicide 23 (0.6) Other known * 244 (4) Unknown 283 (7) *fewer than 20 deaths per stated cause

13 Changes in causes of death over time 1999-2000 N=255 2009-2011 N=548

14 Association between calendar year and mortality: AIDS related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted 5 3 2 4 1 0.1 0.5

15 Association between calendar year and mortality: AIDS related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted (all factors except CD4 count)* 5 3 2 4 1 0.1 0.5

16 Association between calendar year and mortality: AIDS related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted (all factors except CD4 count)* Adjusted* 5 3 2 4 1 0.1 0.5

17 Association between calendar year and mortality: Liver-related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted 5 3 2 4 1 0.1 0.5

18 Association between calendar year and mortality: Liver-related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted* 5 3 2 4 1 0.1 0.5

19 Association between calendar year and mortality: Liver-related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted (all factors except HBV)* Adjusted* 5 3 2 4 1 0.1 0.5

20 Association between calendar year and mortality: Liver-related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted (all factors except HCV)* Adjusted* 5 3 2 4 1 0.1 0.5

21 Association between calendar year and mortality: CVD-related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year Unadjusted 5 3 2 4 1 0.1 0.5

22 Association between calendar year and mortality: CVD-related 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted* 5 3 2 4 1 0.1 0.5

23 Association between calendar year and mortality: Non-AIDS malignancy* 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year Unadjusted * Includes lung cancers, prostate cancers, anal cancers, Hodgkin’s lymphomas, primary liver cancers, gastrointestinal cancers, breast cancers, uterus cancers, testicular cancers, bladder cancers and leukemias 5 3 2 4 1 0.1 0.5

24 Association between calendar year and mortality: Non-AIDS malignancy 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted* 5 3 2 4 1 0.1 0.5

25 Association between calendar year and mortality: Other/Unknown 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year Unadjusted 5 3 2 4 1 0.1 0.5

26 Association between calendar year and mortality: Other/Unknown 1999/ 2000 2001/ 2002 2003/ 2004 2005/ 2006 2007/ 2008 Calendar year * Adjusted for: age, gender, ethnicity, mode of HIV acquisition (fixed) and HBV, HCV, smoking, diabetes, hypertension, HIV RNA, BMI, CD4 count (time-updated) Unadjusted Adjusted* 5 3 2 4 1 0.1 0.5

27 Sensitivity analyses Adjustment for HIV RNA levels does not affect trends over time (once accounting for CD4 count) Results remain consistent when accounting for the presence of any competing risks (from the other causes of death)

28 Summary and discussion Death rates in HIV-positive people with access to care has continued to decline in the cART era There is no indication of any increase in risk of death from any specific cause as a potential result of long term adverse effects of ART This provides continued strong support for the substantial net benefits of ART AIDS remains the leading cause of death Decline in AIDS-related deaths is largely explained by improvements in CD4 count

29 Summary and discussion NADM are now the leading non-AIDS cause of death; rates have remained stable over time Liver and CVD-related deaths have decreased markedly, suggesting improvements in patient management Further work studying the impact of CVD-related interventions (e.g. statins, revascularisation) is on-going Continued monitoring on specific causes of death in HIV is important to allow earlier interventions in HIV case management

30 Steering Committee: Members indicated w/ *; ¢ chair; Cohort PIs: W El-Sadr* (CPCRA), G Calvo* (BASS), F Dabis* (Aquitaine), O Kirk* (EuroSIDA), M Law* (AHOD), A d’Arminio Monforte* (ICONA), L Morfeldt* (HivBIVUS), C Pradier* (Nice), P Reiss* (ATHENA), R Weber* (SHCS), S De Wit* (Brussels) Cohort coordinators and data managers: S Zaheri, M Hillebreght (ATHENA), M Bruyand, S Geffard, (Aquitaine), K Petoumenos, H McManus, S Wright (AHOD), S Mateu, F Torres (BASS), M Delforge (Brussels), G Bartsch, G Thompsen (CPCRA), J Kjær (EuroSIDA), Iuri Fanti (ICONA), E Fontas, C Caissotti (Nice), A Sundström, G Thulin (HivBIVUS), M Rickenbach (SHCS) Statisticians: CA Sabin*, AN Phillips*, A Mocroft, DA Kamara, CJ Smith Community representative: Xavi Franquet* D:A:D coordinating office: L Ryom, R Brandt, J Tverland, JD Lundgren*¢ Member of the D:A:D Oversight Committee: B Powderly*, N Shortman*, R Rode*, D Butcher* Funding: ‘Oversight Committee for The Evaluation of Metabolic Complications of HAART’ with representatives from academia, patient community, FDA, EMEA and a consortium of ”Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healtcare, Merck, Pfizer, F. Hoffmann-La Roche and Janssen Pharmaceuticals D:A:D Study Group

Download ppt "Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011 CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, J Kowalska,"

Similar presentations

1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.

1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.
The results of the Study of Heart and Renal Protection (SHARP)

The results of the Study of Heart and Renal Protection (SHARP)
The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.

The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.
WHITE BLOOD CELL COUNT SECULAR TREND AND MORTALITY: THE BALTIMORE LONGITUDINAL STUDY OF AGING C.Ruggiero; E.J.Metter; A.Cherubini; M.Maggio; R.Sen; S.S.Najjar;

WHITE BLOOD CELL COUNT SECULAR TREND AND MORTALITY: THE BALTIMORE LONGITUDINAL STUDY OF AGING C.Ruggiero; E.J.Metter; A.Cherubini; M.Maggio; R.Sen; S.S.Najjar;
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,

Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
Valsartan Antihypertensive Long-Term Use Evaluation Results

Valsartan Antihypertensive Long-Term Use Evaluation Results
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.

The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute

Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.

Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:1349-57.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Abstract: WEABO205. HIV infection was associated with an increased risk of hip fracture,

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Abstract: WEABO205. HIV infection was associated with an increased risk of hip fracture,
Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.

Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.
UKPDS Paper 81 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.

UKPDS Paper 81 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.
Www.aodhealth.org 1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Lancet 2005 366: 1267-1134 doi:10.1016/S0140-6736(08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
HIV and STI Department - Centre for Infections Predictors of non-AIDS related death in a national cohort of HIV-diagnosed adults Meaghan Kall, Ruth Smith,

HIV and STI Department - Centre for Infections Predictors of non-AIDS related death in a national cohort of HIV-diagnosed adults Meaghan Kall, Ruth Smith,
NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,

NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.

HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Henry N. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.

Henry N. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Risk of serious disease and death in people with HIV viral suppression on ART: an epidemiologic perspective The Lancet and Cell Meeting What Will it Take.

Risk of serious disease and death in people with HIV viral suppression on ART: an epidemiologic perspective The Lancet and Cell Meeting What Will it Take.

Similar presentations

Ads by Google